Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment

Rohan Garje; Josiah J An; Kevin Sanchez; Austin Greco; Jeffrey Stolwijk; Eric Devor; Youcef Rustum; Yousef Zakharia

doi:10.3390/ijms19123834

Back

Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment

Journal article

Open access

Peer reviewed

Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment

Rohan Garje, Josiah J An, Kevin Sanchez, Austin Greco, Jeffrey Stolwijk, Eric Devor, Youcef Rustum and Yousef Zakharia

International Journal of Molecular Sciences, Vol.19(12), p.3834

2018

DOI: 10.3390/ijms19123834

PMID: 30513765

Files and links (1)

url

https://doi.org/10.3390/ijms19123834View

Published (Version of record) Open Access

Abstract

In the last two decades, the discovery of various pathways involved in renal cell carcinoma (RCC) has led to the development of biologically-driven targeted therapies. Hypoxia-inducible factors (HIFs), angiogenic growth factors, von Hippel–Lindau ( VHL ) gene mutations, and oncogenic microRNAs (miRNAs) play essential roles in the pathogenesis and drug resistance of clear cell renal cell carcinoma. These insights have led to the development of vascular endothelial growth factor (VEGF) inhibitors, Mechanistic target of rapamycin (mTOR) inhibitors, and immunotherapeutic agents, which have significantly improved the outcomes of patients with advanced RCC. HIF inhibitors will be a valuable asset in the growing therapeutic armamentarium of RCC. Various histone deacetylase (HDAC) inhibitors, selenium, and agents like PT2385 and PT2977 are being explored in various clinical trials as potential HIF inhibitors, to ameliorate the outcomes of RCC patients. In this article, we will review the current treatment options and highlight the potential role of selenium in the modulation of drug resistance biomarkers expressed in clear cell RCC (ccRCC) tumors.

clear cell renal cell carcinoma

selenium

VEGF

PD-L1

mTOR inhibitors

miRNA

Review

hypoxia-inducible factors (HIFs)

Details

Title: Subtitle: Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment
Creators: Rohan Garje - Roswell Park Cancer Institute, Buffalo, NY 14203, USA
Josiah J An - Roswell Park Cancer Institute, Buffalo, NY 14203, USA
Kevin Sanchez - Roswell Park Cancer Institute, Buffalo, NY 14203, USA
Austin Greco - Roswell Park Cancer Institute, Buffalo, NY 14203, USA
Jeffrey Stolwijk - University of Iowa
Eric Devor - Roswell Park Cancer Institute, Buffalo, NY 14203, USA
Youcef Rustum - Roswell Park Cancer Institute, Buffalo, NY 14203, USA
Yousef Zakharia - Roswell Park Cancer Institute, Buffalo, NY 14203, USA
Resource Type: Journal article
Publication Details: International Journal of Molecular Sciences, Vol.19(12), p.3834
DOI: 10.3390/ijms19123834
PMID: 30513765
NLM abbreviation: Int J Mol Sci
ISSN: 1661-6596
eISSN: 1422-0067
Publisher: MDPI
Language: English
Date published: 2018
Academic Unit: Obstetrics and Gynecology; Radiation Research Laboratory; Internal Medicine
Record Identifier: 9983931823602771

Metrics

34 Record Views

24 Times Cited - Web of Science

See more details